Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 447 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IV Fluids Clear all
Completed No phase listed Observational

Analgesic Efficacy of Orally Administered VTS-K for Pain Management

NCT04702555
View directory record Official record
Conditions
Pain, Acute
Interventions
VTS-K
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 110 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 22, 2026, 5:12 AM EDT
Completed No phase listed Observational

Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC

NCT03302325
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
research blood draws
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 5:12 AM EDT
Terminated No phase listed Observational

Compensatory Reserve Index (CRI) for Management of COVID-19

NCT04457817
View directory record Official record
Conditions
COVID
Interventions
CRI
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

NCT01175213
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Cypress, California • Irvine, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 22, 2026, 5:12 AM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 5:12 AM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue

NCT00855088
View directory record Official record
Conditions
HIV/AIDS, HIV Infections
Interventions
darunavir, Ritonavir, Etravirine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 22, 2026, 5:12 AM EDT
Recruiting No phase listed Observational

The APS Phenotyping Study

NCT06521502
View directory record Official record
Conditions
ARDS, Sepsis, Pneumonia
Interventions
Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan
Other · Procedure · Radiation
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT03848845
View directory record Official record
Conditions
Multiple Myeloma
Interventions
belantamab mafodotin, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Triferic Pediatric Pharmacokinetic Protocol

NCT02595437
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Loma Linda, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 22, 2026, 5:12 AM EDT
Completed No phase listed Observational Results available

Use of Hextend in Trauma

NCT00983281
View directory record Official record
Conditions
Trauma
Interventions
Hextend
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

NCT03792971
View directory record Official record
Conditions
Healthy
Interventions
Dextromethorphan HBr, GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Not applicable Interventional

DYNA EMBOLIZATION - Pilot Study of IV Dyna CT and CBV Imaging Techniques

NCT03528200
View directory record Official record
Conditions
Brain Lesions
Interventions
Contrast
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 22, 2026, 5:12 AM EDT
Withdrawn Not applicable Interventional

Philadelphia Immediate Transport in Penetrating Trauma Trial

NCT02821364
View directory record Official record
Conditions
Hemorrhagic Shock, Peritonitis
Interventions
Advanced Life Support
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Peroral Endoscopic Myotomy (POEM) for Esophageal Motility

NCT02314741
View directory record Official record
Conditions
Achalasia
Interventions
POEM Procedure
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Not applicable Interventional

The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients

NCT03938584
View directory record Official record
Conditions
Vitamin C Deficiency, Smoking, Surgery, Surgery--Complications, Wound, Wound Complication, Wound Infection, Wound Dehiscence, Wound of Skin, Mandible Fracture, Mandible Open Fracture, Mandible Closed Fracture, Mandibular Fractures, Ascorbic Acid Deficiency, Oxidative Stress, Inflammation
Interventions
Vitamin C, Placebo
Dietary Supplement · Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 22, 2026, 5:12 AM EDT
Active, not recruiting Not applicable Interventional

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

NCT01464606
View directory record Official record
Conditions
Pleuropulmonary Blastoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Ifosfamide, Doxorubicin
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 22, 2026, 5:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pancreas Ultrasound Imaging in type1 Diabetes

NCT05482321
View directory record Official record
Conditions
Type1diabetes, Insulitis, Pancreas Inflamed
Interventions
Definity Suspension for Injection
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 5:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease

NCT02947022
View directory record Official record
Conditions
Headache, Cognitive Disturbance, Skin Hyperpigmentation, Arthralgia
Interventions
Calcium DTPA, Zinc DTPA
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Clinical Trial: Expectant Management vs Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation and Absent or Reverse Diastolic Flow in the Umbilical Artery

NCT01177553
View directory record Official record
Conditions
Intrauterine Growth Retardation
Interventions
selective laser photocoagulation of communicating vessels, Expected Management
Procedure · Device
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Alvimopan as a Rescue Treatment of Postoperative Ileus

NCT04405037
View directory record Official record
Conditions
Ileus, Gastrointestinal Dysfunction
Interventions
Alvimopan
Drug
Lead sponsor
Scott Steele
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)

NCT00233064
View directory record Official record
Conditions
Chronic Lung Disease
Interventions
Lyophilized Palivizumab, Liquid Palivizumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
Up to 24 Months
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Hoover, Alabama • Tuscaloosa, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Early Phase 1 Interventional Results available

Effects of Flavors on Nicotine Reinforcement in Smokers

NCT03243630
View directory record Official record
Conditions
Nicotine Dependence
Interventions
IV nicotine, Menthol flavor, green apple, green apple and menthol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 22, 2026, 5:12 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

NCT05586581
View directory record Official record
Conditions
HIV Associated Neurocognitive Disorder, HIV Dementia, HIV Encephalitis, Healthy
Interventions
SV2A PET, TSPO PET
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 5:12 AM EDT